Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

The objective of this study is to show that ranolazine is a safe, viable and potent alternative for post-operative atrial fibrillation suppression in patients undergoing cardiac surgery

A single center, double blind, prospective, randomized study for patients who are scheduled for elective cardiac surgery (Coronary Artery Bypass Graft [CABG], or valve or CABG and valve). All patients who meet criteria will be prospectively enrolled in a randomized fashion. Patients enrolled will be assigned to receive twice daily identical capsules containing either placebo or ranolazine. Study drug will be initiated 2 days before surgery. Patients will receive study drug throughout their hospitalization and be kept on it for a full 2 weeks post operatively. Patients will be seen in 2 weeks and receive a 30 day follow up contact visit.

Inclusion Criteria:

• Indications for cardiac surgery (CABG, valve surgery or CABG and valve surgery, Able to provide informed consent.

Exclusion Criteria:

• Documented atrial fibrillation within the previous 3 months
• Ongoing therapy with suppressive antiarrhythmic drugs
• Patient currently on digoxin
• Emergent surgery
• Patient receiving hemodialysis
• Concomitant use of ketoconazole, diltiazem, verapamil
• Known tolerance or hypersensitivity to ranolazine
• Pregnant individuals
• MAZE procedure (is a surgical ablation to treat atrial fibrillation) performed during concurrent cardiac surgery